S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:AEZS

Aeterna Zentaris (AEZS) Stock Price, News & Analysis

$2.19
+0.11 (+5.29%)
(As of 03/28/2024 ET)
Today's Range
$2.01
$2.19
50-Day Range
$1.71
$2.19
52-Week Range
$1.36
$3.38
Volume
49,543 shs
Average Volume
17,157 shs
Market Capitalization
$10.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Aeterna Zentaris MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
584.9% Upside
$15.00 Price Target
Short Interest
Healthy
0.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.10mentions of Aeterna Zentaris in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.22) to ($3.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.68 out of 5 stars

Medical Sector

761st out of 938 stocks

Pharmaceutical Preparations Industry

340th out of 417 stocks

AEZS stock logo

About Aeterna Zentaris Stock (NASDAQ:AEZS)

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

AEZS Stock Price History

AEZS Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Aeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update
AEterna Zentaris: Q4 Earnings Insights
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Aeterna Zentaris Inc.
AEterna Zentaris Inc AEZS
Aeterna Zentaris GAAP EPS of -$0.85
Closing Bell: Aeterna Zentaris Inc down on Monday (AEZS)
Closing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)
H.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)
See More Headlines
Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AEZS
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+584.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-22,730,000.00
Net Margins
-340.56%
Pretax Margin
-340.56%

Debt

Sales & Book Value

Annual Sales
$5.64 million
Book Value
$7.37 per share

Miscellaneous

Free Float
4,851,000
Market Cap
$10.64 million
Optionable
No Data
Beta
1.56

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Klaus Paulini Ph.D.
    President, CEO & Executive Director
  • Mr. Giuliano La Fratta
    Senior VP of Finance & CFO
  • Dr. Michael Teifel Ph.D.
    Senior VP of Non-Clinical Development & Chief Scientific Officer
  • Dr. Nicola Ammer M.D.
    Chief Medical Officer & Senior VP of Clinical Development
  • Dr. Matthias Gerlach
    Senior Vice President Manufacturing & Supply Chain

AEZS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings
or view top-rated stocks.

What is Aeterna Zentaris' stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for Aeterna Zentaris' stock. Their AEZS share price targets range from $15.00 to $15.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 584.9% from the stock's current price.
View analysts price targets for AEZS
or view top-rated stocks among Wall Street analysts.

How have AEZS shares performed in 2024?

Aeterna Zentaris' stock was trading at $1.86 at the start of the year. Since then, AEZS shares have increased by 17.7% and is now trading at $2.19.
View the best growth stocks for 2024 here
.

Are investors shorting Aeterna Zentaris?

Aeterna Zentaris saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 29,200 shares, an increase of 46.0% from the February 29th total of 20,000 shares. Based on an average trading volume of 16,800 shares, the days-to-cover ratio is presently 1.7 days. Currently, 0.6% of the shares of the company are sold short.
View Aeterna Zentaris' Short Interest
.

When is Aeterna Zentaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AEZS earnings forecast
.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.25. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to analysts' expectations of $0.60 million. Aeterna Zentaris had a negative trailing twelve-month return on equity of 49.10% and a negative net margin of 340.56%.

When did Aeterna Zentaris' stock split?

Shares of Aeterna Zentaris reverse split before market open on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?
Who are Aeterna Zentaris' major shareholders?

Aeterna Zentaris' stock is owned by many different institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AEZS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners